Stoke Therapeutics
STOK
93 hedge funds and large institutions have $2.39B invested in Stoke Therapeutics in 2020 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 11 closing their positions.
842% more call options, than puts
Call options by funds: $4.78M | Put options by funds: $507K
106% more capital invested
Capital invested by funds: $1.16B → $2.39B (+$1.23B)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
6% more funds holding
Funds holding: 88 → 93 (+5)
3.25% more ownership
Funds ownership: 104.19% → 107.44% (+3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$76.1M |
| 2 |
Goldman Sachs
New York
|
+$21.5M |
| 3 |
BlackRock
New York
|
+$19.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.4M |
| 5 |
ALSV
ATP Life Science Ventures
New York
|
+$17.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.58M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.44M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$3.21M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.83M |
| 5 |
Aviva
London,
United Kingdom
|
-$1.37M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Simplex Trading
Chicago,
Illinois
| – | -$55.1K | -1,202 | Closed |
|
102
US Bancorp
Minneapolis,
Minnesota
| – | -$20K | -600 | Closed |
|
|
TPWA
103
TRUE Private Wealth Advisors
Salem,
Oregon
| – | -$13K | -400 | Closed |
|
|
PFWA
104
Paces Ferry Wealth Advisors
Atlanta,
Georgia
| – | -$3K | -100 | Closed |
|
STOK Hedge Fund Activity: Q4 2020 in Review
93 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q4 2020, worth a combined $2.39B — up 106% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new STOK positions and 11 closed out — a net gain of 5 holders — while 32 added to existing stakes and 25 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $76.1M. The largest seller was Cormorant Asset Management, cutting an estimated $4.58M.
- 93 institutional investors held Stoke Therapeutics (STOK) as of Q4 2020, up from 88 in Q3 2020.
- Funds reported $2.39B of Stoke Therapeutics stock for Q4 2020, up 106% quarter-over-quarter.
- 16 funds opened new Stoke Therapeutics positions in Q4 2020 and 11 closed out, a net change of +5 holders.
- The largest Stoke Therapeutics buyer in Q4 2020 was Fidelity Investments, an estimated $76.1M added.
- The largest Stoke Therapeutics seller in Q4 2020 was Cormorant Asset Management, an estimated $4.58M sold.
Based on aggregated 13F filings for Q4 2020.